Radiotherapy has long been a cornerstone in the multimodal treatment of cancer, valued for its ability to destroy localized tumors through DNA damage and cellular apoptosis. Traditionally, its immunomodulatory impact was considered beneficial; radiation could often activate systemic anti-tumor immunity, resulting in the regression of untreated distant tumors – the abscopal effect. This phenomenon has fueled hope that radiation could be harnessed not just as a local weapon but as a systemic therapeutic agent to combat metastatic disease. However, real-world clinical outcomes have been inconsistent, particularly in patients with oligometastatic disease receiving stereotactic body radiotherapy (SBRT) combined with immunotherapy. Many patients fail to exhibit sustained systemic tumor control and even experience progression of untreated metastases.

The team led by Dr. Ralph Weichselbaum, a pioneering figure in radiation and cellular oncology, hypothesized that under certain conditions, high radiation doses might paradoxically facilitate tumor progression at unirradiated metastatic sites. This insight has profound implications for understanding treatment failures and guiding future therapeutic strategies. To rigorously explore this, researchers analyzed biopsies from patients enrolled in clinical trials where SBRT was administered alongside checkpoint inhibitors like pembrolizumab. Strikingly, they found that some untreated metastatic lesions grew post-radiation, signaling that radiotherapy might unwittingly signal and feed distant tumor expansion.

Delving deeper into the molecular mechanisms underlying this phenomenon, postdoctoral fellow Dr. András Piffkó and collaborators conducted gene expression profiling in irradiated tumor samples. Their analysis unveiled a significant upregulation of amphiregulin, a ligand for the epidermal growth factor receptor (EGFR), in tumor cells exposed to high-dose radiation. Amphiregulin’s binding to EGFR triggers phosphorylation cascades that promote cellular survival, proliferation, migration, and resistance to apoptosis—pathways well known for their contributions to tumor aggressiveness.

To substantiate the clinical observations, sophisticated animal models of lung and breast cancer metastasis were employed. These studies showed a marked dichotomy: while radiation curtailed the emergence of new metastatic foci, it simultaneously accelerated the growth kinetics of established metastatic tumors. This dual effect hinged on the induction of amphiregulin, which was markedly elevated both within the tumor microenvironment and systemically in the bloodstream after radiotherapy. Crucially, therapeutic interventions that blocked amphiregulin function—either through neutralizing antibodies or CRISPR-mediated gene knockout in tumor cells—successfully curtailed the growth of distant metastases, even outside the radiation field. The findings suggest amphiregulin is a critical molecular mediator of the badscopal effect.

Furthermore, the researchers uncovered a complex interplay between amphiregulin and the host immune system’s capacity to surveil and eliminate cancer cells. Elevated amphiregulin correlated with an increase in immunosuppressive myeloid cells, which are known to dampen anti-tumor immune responses. This immune cell population exhibits phenotypes that inhibit cytotoxic T cell activity and promote tumor tolerance. Prior work from the same group had demonstrated that ablating these myeloid subsets reduces metastatic burden; in contrast, amphiregulin expression appeared to skew myeloid cell differentiation towards an immunosuppressive state.

Another critical element involved the upregulation of CD47, a macrophage “don’t eat me” signal, in amphiregulin-high tumors following radiation. This molecular cloak impairs macrophage and myeloid cell phagocytic activity, enabling tumor cells to evade innate immune elimination. Collaborations with biochemistry experts led to the pivotal discovery that targeting both amphiregulin and CD47 concurrently, alongside radiotherapy, produced robust control over metastatic disease in preclinical models. This combinatorial strategy effectively counteracted the badscopal effect and restored systemic tumor suppression.

These results compel a paradigm shift in how radiotherapy is conceptualized and applied in oncologic care, particularly in the metastatic setting. Rather than viewing radiation as purely an immunostimulatory approach, clinicians and researchers must now consider its potential to induce tumor-promoting factors like amphiregulin that can subvert immune surveillance. Monitoring amphiregulin expression levels post-radiotherapy could serve as a biomarker to identify patients at risk for metastatic progression, guiding more personalized and adaptive treatment regimens.

The study’s authors are vigorously planning clinical trials that integrate amphiregulin and CD47 blockade with conventional radiotherapy to validate this approach in humans. If successful, this innovation could revolutionize the management of metastatic cancers, transforming radiotherapy from a blunt instrument into a precision therapy tailored to counteract its own adverse systemic effects.

Dr. Weichselbaum emphasized, “Our findings open an entirely new dimension in studying radiation’s systemic influence. Radiation is no longer just a local treatment but a modulator of tumor biology throughout the body. With appropriate molecular interventions, we can harness its full therapeutic potential while neutralizing unintended tumor-promoting signals.”

This landmark discovery also highlights the broader need for integrating molecular biology, immunology, and radiation oncology to unravel the complex interdependencies that govern cancer progression and response to therapy. As metastasis remains the leading cause of cancer mortality, insights from this study will have wide-reaching implications for developing next-generation cancer therapies.

The work was supported by prominent funding sources including the National Cancer Institute and Ludwig Foundation, reflecting the critical importance and translational promise of these findings. With contributions from a multidisciplinary team spanning institutions globally, this research exemplifies the power of collaborative science to transform cancer treatment paradigms.

Subject of Research: Human tissue samples

Article Title: Radiation-induced amphiregulin drives tumour metastasis

News Publication Date: 14-May-2025

Web References:
https://www.nature.com/articles/s41586-025-08994-0

References:
Piffkó A., Yang K., Panda A., et al. (2025). Radiation-induced amphiregulin drives tumor metastasis. Nature. https://doi.org/10.1038/s41586-025-08994-0

Keywords:
Clinical medicine, Cancer treatments, Radiation therapy, Synchronous radiation, Combination therapies, Drug combinations, Cancer, Cell pathology, Radiology, Oncology, Tumor growth, Metastasis

The intricate realms of epigenetics and epitranscriptomics are crucial for understanding the mechanisms that modify gene expression without changing the underlying genetic code. One of these processes involves N6-methyladenosine, or m6A, where methyl groups are added to the N6 position of adenosine in RNA molecules. This modification plays a vital role in enhancing RNA stability, which is crucial for normal cellular functions. However, the removal of these methyl groups by enzymes such as FTO has been shown to facilitate tumor development, highlighting the dual nature of RNA modifications in cancer.

FTO stands out as the first identified m6A demethylase and has been observed to be upregulated in various forms of cancer. A team led by Dr. Yu-Ying He, a respected professor of medicine in the dermatology section at the University of Chicago, undertook a comprehensive study to identify compounds capable of degrading FTO. The implications of targeting FTO for cancer treatment are vast, considering its significant role in obesity-related malignancies.

Interestingly, FTO has drawn researchers’ attention even before its association with RNA modification came to light. In earlier investigations conducted by Dr. He and her colleagues, they found elevated levels of FTO in melanoma, a notoriously aggressive type of skin cancer. Their research highlighted environmental factors, including exposure to UV radiation and arsenic, which contribute to heightened levels of FTO, resulting in decreased RNA modifications in melanoma, thereby fostering tumor growth.

While the search for small molecule FTO inhibitors has unfolded, many of these candidates faced hurdles concerning their clinical utility. Concerns about unknown or undesirable toxicity profiles raised red flags regarding their viability as therapeutic agents. In light of these challenges, Dr. He’s collaboration with Dr. Chuan He, a distinguished professor of chemistry at the University of Chicago, was pivotal. Together, they screened an array of compounds, ultimately identifying vitamin E succinate as a potential FTO degrader.

The safety profile of VES is particularly noteworthy, as it is already widely utilized as a dietary supplement. This characteristic distinguishes it from other small molecule FTO inhibitors that might come with unknown risks. The researchers employed molecular docking techniques to validate their findings, confirming that VES binds effectively to FTO, thereby promoting its degradation. In contrast, other vitamins and derivatives of vitamin E lacked the same effect, emphasizing VES’s unique potential.

Delving deeper into the molecular mechanisms, the researchers established that the degradation of proteins like FTO is typically mediated by E3 ubiquitin ligases. Subsequently, the study identified DTX2 as the E3 ubiquitin ligase involved in facilitating the degradation of FTO in response to VES. This critical finding strengthens the understanding of how VES operates at a molecular level, positioning it as a novel therapeutic candidate in cancer treatment.

The mechanism of action of vitamin E succinate is intriguing; it is comprised of two primary components—succinate and vitamin E. Succinate binds to FTO, while vitamin E binds to DTX2, effectively uniting these two molecules. This interaction facilitates the degradation of FTO, functioning analogously to a molecular glue that brings the necessary players together to initiate the degradation process.

The implications of these findings extend beyond understanding FTO degradation. The research team conducted a series of experiments to decipher how VES could alleviate tumorigenesis and heighten tumor sensitivity to immunotherapy. Their work ultimately demonstrated that VES enhances T-cell mediated cytotoxicity through the intrinsic suppression of FTO within tumors, offering a new angle for enhancing immunotherapeutic strategies.

As a dietary supplement with a well-known safety profile, vitamin E succinate holds immense promise as a therapeutic intervention for cancers characterized by elevated FTO levels, which are often resistant to conventional immunotherapy. This discovery sets the stage for future clinical trials aimed at integrating VES into the treatment protocols of resistant cancer types, potentially improving outcomes for many patients.

The wealth of knowledge from this study conduces to a greater understanding of the multifaceted roles that epitranscriptomics play in cancer biology. Consequently, ongoing research into FTO inhibitors and derivatives stands to contribute significantly toward innovative cancer treatment strategies that more effectively exploit the immune system’s capabilities.

In summary, the identification of vitamin E succinate as a viable FTO degrader represents a landmark moment in cancer research. The synergy between dietary supplements and targeted therapies emphasizes the potential of repurposing existing compounds to address pressing challenges in oncology, particularly in the fight against drug-resistant cancers.

Subject of Research: Vitamin E succinate’s role in FTO degradation and its implications for cancer immunotherapy.
Article Title: Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.
News Publication Date: 17-Dec-2024.
Web References: PNAS Article
References: Research on FTO link to obesity and cancer, Dr. Yu-Ying He’s prior studies on melanoma and environmental factors, collaboration with Dr. Chuan He.
Image Credits: N/A

Keywords: Vitamin E, tumor growth, cancer immunotherapy, FTO, epitranscriptomics.

This study is particularly pivotal as it not only contradicts the dominant narrative surrounding alcohol use and psychological distress but also provides a clearer understanding of the motivations behind drinking behaviors in individuals with dual diagnoses. The lead author, Dr. Andrea King, a distinguished professor of psychiatry and behavioral neuroscience at the University of Chicago, emphasizes that the prevailing mythology holds that people resort to excessive drinking mainly for self-medication purposes. This exhaustive research sheds light on the fact that these individuals are not merely attempting to numb negative experiences; they also derive substantial joy and rewarding effects from alcohol consumption.

Published in the prestigious American Journal of Psychiatry on February 1, the findings signify a crucial shift in how we might approach the treatment of those suffering from AUD and concurrent depressive disorders. Traditionally, the focus of treatment methods has been centered around addressing stress and the symptoms of depression. This study underscores the importance of also considering the significant positive reinforcement and pleasurable feelings experienced during intoxication. According to Dr. King, it becomes increasingly vital for treatment providers to acknowledge that individuals with AUD may not only be consuming alcohol to self-medicate but may also genuinely enjoy its stimulating effects, which can complicate efforts to assist these individuals in overcoming their dependencies.

Another important aspect of this study is its methodology. The researchers observed and analyzed the drinking behaviors of 232 participants aging from 21 to 35 years—an age bracket known for high incidences of heavy drinking. They employed innovative real-time reporting methods using smartphones to monitor participants’ responses to alcohol in both casual drinking situations and non-drinking episodes. Through this approach, the research team discovered that while alcohol does lead to a marginal decrease in negative feelings in those with AUD, this effect is largely unrelated to their depression status. In contrast, the pleasure derived from drinking was markedly higher among those with AUD compared to non-AUD drinkers, suggesting that the intoxicating effects of alcohol could largely be a unifying experience regardless of comorbid depressive disorders.

Understanding this perspective provides a new lens for evaluating the psychological and neurological factors that contribute to addiction. The complex relationship between alcohol and the brain has long been a subject of research, particularly regarding how heavy drinking may alter brain pathways associated with stress and reward. The established theory of a "dark side" of addiction posits that repeated heavy use shifts an individual’s motivation from seeking pleasure to attempting to avoid withdrawal symptoms and stress. However, Dr. King argues that such a theoretical framework fails to explain the compelling evidence of increased pleasure experienced during intoxication, which could potentially drive ongoing dependency.

The insights from this study indicate a paradigm shift centered on re-evaluating how treatment strategies are designed for individuals with AUD and depression. Presently, treatment programs are steeped in the belief that the principal motivation for drinking stems from the need to escape negative feelings. However, the new findings suggest a dual pathway is at play—where pleasure-seeking behaviors cannot be overlooked in any therapeutic approach. This has significant implications for the development of more effective treatment modalities that recognize the intrinsic enjoyment derived from alcohol, leading to more holistic and customized intervention plans.

Moreover, understanding that individuals with AUD also find pleasure in drinking underscores the importance of nuanced treatment strategies. This research hints at the potential for clinical practices to evolve, allowing treatment providers to not only address the harmful repercussions of alcohol abuse but also the underlying allure it holds. King articulates that the contemporary approach to treatment is far too narrow and is missing a vital piece of the puzzle—acknowledging the positive stimuli that encourage excessive drinking behavior in both depressed and non-depressed individuals.

As part of advancing this line of inquiry, Dr. King’s upcoming study aims to investigate whether older adults—specifically those aged 40 to 65 with long-term AUD—continue to experience heightened pleasure when consuming alcohol, akin to the findings exhibited in younger participants of a prior study. The prevailing belief is that with age, individuals develop a blunted response to alcohol’s effects, leading to increased tolerance. However, the screening of this new population may yield surprising insights, calling into question previous theories surrounding addiction and age.

The implications of this research are profound, pushing the boundaries on how society and medical professionals view alcohol consumption and its multifaceted impacts on individuals living with mental health issues. As we continue to uncover the underlying mechanisms of addiction, awareness around how pleasure influences drinking behaviors could lead to implementation changes in both prevention and treatment efforts, ultimately fostering a greater understanding of addiction as a complex interplay of desires driven by both negative and positive reinforcement.

In conclusion, the research conducted by Dr. Andrea King and her colleagues at the University of Chicago Medicine signifies a turning point in the study of alcohol use disorder and depression. While it has been well-documented that alcohol can exacerbate depressive symptoms, the newfound understanding that drinking can also evoke pleasure illuminates a crucial aspect of human behavior that cannot be ignored. As scientists work towards comprehensively unpacking the layers of addiction, the knowledge gleaned from this study heralds a new beginning for treatment methodologies that embrace the totality of the human experience—both its challenges and its joys.

Subject of Research: Individuals with Alcohol Use Disorder and Depressive Disorders
Article Title: Real-Time Assessment of Positive and Negative Alcohol Effects in Individuals With and Without Alcohol Use Disorder and Depressive Disorders
News Publication Date: February 1, 2024
Web References: DOI link to the study
References: American Journal of Psychiatry
Image Credits: N/A

Keywords: alcohol use disorder, depression, pleasure, treatment, addiction, University of Chicago, psychiatry, neuroscience